MaxCyte, Inc. (MXCT)
NASDAQ: MXCT · Real-Time Price · USD
2.250
-0.020 (-0.88%)
At close: Jul 25, 2025, 4:00 PM
2.330
+0.080 (3.56%)
After-hours: Jul 25, 2025, 7:21 PM EDT
MaxCyte Employees
MaxCyte had 114 employees as of December 31, 2024. The number of employees decreased by 29 or -20.28% compared to the previous year.
Employees
114
Change (1Y)
-29
Growth (1Y)
-20.28%
Revenue / Employee
$330,482
Profits / Employee
-$366,579
Market Cap
239.44M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 114 | -29 | -20.28% |
| Dec 31, 2023 | 143 | 18 | 14.40% |
| Dec 31, 2022 | 125 | 41 | 48.81% |
| Dec 31, 2021 | 84 | 19 | 29.23% |
| Dec 31, 2019 | 65 | 33 | 103.13% |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MXCT News
- 17 days ago - MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025 - GlobeNewsWire
- 25 days ago - PHC Announces Exclusive Distribution of MaxCyte® ExPERT™ Platform in Japan - Business Wire
- 6 weeks ago - MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies - GlobeNewsWire
- 2 months ago - MaxCyte, Inc. (MXCT) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance - GlobeNewsWire
- 3 months ago - MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025 - GlobeNewsWire
- 4 months ago - MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share Price - Seeking Alpha
- 4 months ago - MaxCyte, Inc. (MXCT) Q4 2024 Earnings Call Transcript - Seeking Alpha